BioSpace News Archive

ReCode Therapeutics announced today the appointment of April Loui, MBA, CSSBB, as senior vice president of quality and chemical, manufacturing and controls (CMC) regulatory affairs.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022.

Integrated DNA Technologies Expands Access, Expedites Turnaround Time, for Minimal Residual Disease (MRD) Solutions for Cancer Research.

Healint, the developer and owner of Migraine Buddy – the world’s largest migraine tracking and research platform used by more than 3 million people and tens of thousands of migraine and pain clinics – and www.weather-migraine.com - The world first hyperlocal & AI based migraine weather-forecast website - is announcing a collaboration today with the University of Toronto.

Jaguar Health, Inc. and SynWorld Technologies Corporation (SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar’s Canalevia® (crofelemer delayed-release tablets) prescription drug product effective January 31, 2023.

Atreo, Inc., a Clinical Development SaaS company committed to modernizing and simplifying RTSM delivery, has announced release of v1.2 of their next generation platform in advance of SCOPE 2023.

Today, Qrypt, which offers the only solution to remove encryption keys from transmission, announces the launch of its new US-developed, sourced, and hosted QRNG as part of its Quantum Entropy cloud service.

City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that its subsidiary, Cancer Treatment Centers of America®, will fully transition its clinical locations to City of Hope’s brand.

Medigene AG announced the appointment of Pamela Keck as Vice President, Head of Investor Relations and Corporate Communications.

Stemson Therapeutics, a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D’Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific Officer.